Understand · Discuss · Plan together
Risk-Reducing Medicines, Surgery and Lifestyle
Prevention decisions should balance likely benefit, harms, alternatives and the person’s priorities.
Chapter 14 of 16
Explore all 16 chapters
Surgery: substantial choices
| Option | Potential benefit | Trade-offs |
|---|---|---|
| Bilateral risk-reducing mastectomy | Large reduction in breast-cancer incidence for appropriately selected high-risk people. | Risk is not zero; operative complications, sensation, body image and reconstruction choices matter. Survival benefit is not identical in every setting. |
| BRCA risk-reducing salpingo-oophorectomy | Reduces fallopian tube and ovarian cancer risk. Common counselling windows: BRCA1 35–40; BRCA2 40–45, after family completion. | Permanent infertility and premature menopause if premenopausal; some primary peritoneal risk remains. Timing must be individualised. |
| Lynch hysterectomy, with gene-specific ovary discussion | Reduces endometrial cancer risk; ovary decisions depend on gene and clinical factors. | Fertility loss, operative risks and possible menopause; not one operation or age for every Lynch carrier. |
| FAP bowel surgery | Can prevent colorectal cancer when polyp burden warrants surgery. | Bowel function and possible stoma or pouch consequences; surveillance continues after surgery. |
Medicines are not for self-prescribing
Tamoxifen and, in selected postmenopausal women, raloxifene or aromatase inhibitors may reduce hormone-sensitive breast cancer risk. Benefits are not the same across genes or tumour types. Clotting, uterine effects, menopausal symptoms and bone health influence selection. Aspirin may reduce colorectal cancer risk in Lynch syndrome, but dose and duration require clinician agreement, considering bleeding, ulcers, kidney disease and other medicines. Do not start it from this guide.
Lifestyle remains worthwhile
Avoid tobacco, stay physically active, maintain a healthy weight and limit alcohol. These measures support overall health but do not erase a pathogenic variant or replace surveillance. No supplement, detox or special diet is proven to neutralise inherited cancer susceptibility.
Questions before an irreversible decision
- What is my remaining age-specific risk, and how much would this option reduce it?
- What happens if I continue surveillance or defer the procedure?
- How will fertility, menopause, sexual health and long-term follow-up be managed?
- Would a specialist second opinion help me decide?
Sources and further reading
- NCI — Surgery to Reduce the Risk of Breast Cancer
- eviQ — BRCA1 or BRCA2 risk management (female)
- eviQ — MMR genes (Lynch syndrome) risk management
- NCI PDQ — Genetics of Colorectal Cancer
- NCI PDQ — BRCA1 and BRCA2: Cancer Risks and Management
Accessible sources checked: 19 October 2026. International recommendations are identified where used; care in India requires individual clinical assessment. No claim is made to have directly verified restricted NCCN guidance.